

POWERED BY COR2ED

WHAT ARE THE PROS AND CONS OF ADJUVANT TREATMENT IN STAGE II COLORECTAL CANCER?

Priv.-Doz. Dr. Thomas Winder

Academic Teaching Hospital Feldkirch, Austria and Swiss Tumor Molecular Institute, Zurich, Switzerland

Prof. Sebastian Stintzing

University Hospital Munich, Germany

Dr. Shubham Pant

MD Anderson Cancer Center, Houston, TX, USA





Please note:

The views expressed within this presentation are the personal opinions of the authors. They do not necessarily represent the views of the authors' academic institutions or the rest of the GI CONNECT group


ADJUVANT TREATMENT IN STAGE II COLORECTAL CANCER: PRO ARGUMENT

Prof. Sebastian Stintzing

University Hospital, Munich, Germany

STAGE II: ADJUVANT CHEMOTHERAPY INCREASES DFS BY 2-3%





STAGE II: CLINICO-PATHOLOGICAL RISK FACTORS FOR RECURRENCE



UNIVARIABLE RISK OF RECURRENCE FOR COLON CANCER STAGE II-III

Clinicopathological parameter	HR (95% CI) ¹	Patients (n)	Clinicopathological parameter	HR (95% CI) ¹	Patients (n)
pT-stage T1-2 T3	1 1.85 (1.10-3.23)	1167	Neural invasion No Yes	1 1.99 (0.84-4.74)	162
pT-stage T3 T4	1 1.90 (1.08-3.32)	2411	Vascular invasion No Yes	1 2.08 (1.26-3.43)	1281
pN-stage N1 N2	1 2.27 (1.89-2.73)	1707	MMR-status Proficient (MSI-stable) Deficient (MSI-unstable)	1 0.54 (0.41–0.68)	2854
Lymph nodes studied (n) ≥ 12 (15) < 12 (15)	1 1.96 (1.09-3.57)	1052	CEA-level < 5 ng/ml ≥ 5 ng/ml	1 1.85 (0.27-12.6)	162
Differentiation Well/moderate Low	1 1.58 (1.08-2.33)	2795	<i>KRAS</i> -status Wildtype Mutation	1 1.04 (0.85-1.28)	1404
Perforation or obstruction No Yes	1 1.97 (1.11-3.51)	539			

1. Pooled univariable values for risk of recurrence. Both 3- and 5-year hazard ratios were included in this table. Random effects model was used for the meta-analysis.

Böckelman et al. Acta Oncol. 2015 Jan;54(1):5-16

CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio; KRAS, Kirsten Rat Sarcoma; MMR, mismatch repair; MSI, microsatellite instability; pN-stage, pathological nodal stage; pT-stage, pathological tumor stage 6

RELATIVE RISK OF RECURRENCE IN FIRST 2 YEARS AFTER RANDOMISATION BY STAGE AND SITE




POWERED BY COR2ED

	Events/patients		Events in chemotherapy group		Relative risk and Cl	
	Chemotherapy	Observation	(O-E)	Var		
Colon stage II	86/1073 (8·0%)	120/1073 (11·2%)	-17.9	51-5		0·71 (0·49–1·01) (p=0·01)
Rectum stage II	35/410 (8·5%)	60/407 (14·7%)	-13-2	23.7 -		0.57 (0.34-0.97) (p=0.007)
Colon stage III	16/70 (22·9%)	23/67 (34·3%)	-4.7	9.7 —		0.62 (0.27-1.41) (p=0.13)
Rectum stage III	11/61 (18·0%)	23/62 (37·1%)	-7-0	8.5	a	0-44 (0-18-1-06) (p=0-02)
Heterogeneity between four	groups χ³₃=2∙0; p=	=0·57				
Unstratified	148/1614 (9·2%)	226/1609 (14·0%)	-41.7	93.5	\Leftrightarrow	0·64 (0·49–0·84) (p<0·0001
 − Relative risk and 99% CI CI CI Relative risk and 95% CI 				0 Chemoth	0·5 1·0 1·5 erapy better Observation b	2.0

CDX2 EXPRESSION IS A PREDICTIVE FACTOR FOR THE USE OF CHEMOTHERAPY IN STAGE II DISEASE




PATIENTS WITH STAGE II DISEASE



POST-SURGICAL ct-DNA IS A NEW MARKER TO PREDICT RECURRENCE IN STAGE II DISEASE






ADJUVANT TREATMENT OF STAGE II DISEASE: ONE SIZE DOES NOT FIT ALL

Dr. Shubham Pant

MD Anderson Cancer Center, Houston, TX, USA

STAGE II ADJUVANT CHEMOTHERAPY INCREASES DFS BY 2-3%; HOWEVER, NO DIFFERENCE IN OS WAS SEEN IN THE STAGE II POPULATION



conneci

POWERED BY COR2ED

DR. SHUBHAM PANT'S CONCLUSIONS



- Based on the current, available data, adjuvant chemotherapy cannot be considered as a standard of care for all patients with resected stage II disease
- Therapy may be warranted for a subgroup of patients on an individual basis and the oncologist must discuss risks vs. potential of benefit with patients

STAGE II 'HIGH-RISK' DISEASE



Patients with stage II disease are considered at high risk if at least one of the following characteristics are identified:

- 1. Lymph nodes sampling <12
- 2. Poorly differentiated tumor
- 3. Vascular or lymphatic or perineural invasion
- 4. Tumour presentation with obstruction or tumor perforation
- 5. pT4 stage

OVERALL CONCLUSIONS



- There is currently no clear consensus regarding the role of adjuvant treatment in patients with stage II colorectal cancer
- The decision whether to recommend adjuvant therapy should be done on an individual basis, considering patient and tumor characteristics, including pT4 stage and potential molecular factors, such as CDX2
- More data are needed to define the optimal use of adjuvant treatment for patients with stage II colorectal cancer



GI CONNECT Bodenackerstrasse 17 4103 Bottmingen SWITZERLAND

Dr. Antoine Lacombe Pharm D, MBA Phone: +41 79 529 42 79 <u>antoine.lacombe@cor2ed.com</u>

Dr. Froukje Sosef MD Phone: +31 6 2324 3636 <u>froukje.sosef@cor2ed.com</u>

